Release date: 20 October 2020
Promoter – Financial Intermediary
MEDICAL MICROINSTRUMENTS SPA
Quasi-equity financing of MMI, an innovative medtech company based in Italy. The project is dedicated to financing the company's research, development and innovation (RDI) and capex costs for the development of its robotic surgery products.
The proposed transaction will support research and development (R&D) investments required to bring a product to the market addressing a high unmet medical need, in a growing patient population, preserving and cultivating highly skilled employment opportunities.
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 15 million
Total cost (Approximate amount)
EUR 33 million
The Promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending 2011/92/EU. Full environmental details verified during appraisal.
The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Signed - 7/08/2020
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).